Unity Biotechnology, Inc. UBX
We take great care to ensure that the data presented and summarized in this overview for Unity Biotechnology, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding UBX
View allLatest Institutional Activity in UBX
Top Purchases
Top Sells
About UBX
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Insider Transactions at UBX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 04
2024
|
Alexander Hieu Nguyen Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
149
-0.6%
|
$149
$1.29 P/Share
|
|
Nov 04
2024
|
Lynne Marie Sullivan CFO & Head of Corp. Dev. |
SELL
Open market or private sale
|
Direct |
136
-0.24%
|
$136
$1.29 P/Share
|
|
Nov 04
2024
|
Anirvan Ghosh Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
432
-0.57%
|
$432
$1.29 P/Share
|
|
Aug 02
2024
|
Lynne Marie Sullivan CFO & Head of Corp. Dev. |
SELL
Open market or private sale
|
Direct |
139
-0.25%
|
$139
$1.53 P/Share
|
|
Aug 02
2024
|
Anirvan Ghosh Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
604
-0.79%
|
$604
$1.53 P/Share
|
|
Aug 02
2024
|
Alexander Hieu Nguyen Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
154
-0.62%
|
$154
$1.53 P/Share
|
|
Jun 25
2024
|
Lynne Marie Sullivan CFO & Head of Corp. Dev. |
SELL
Open market or private sale
|
Direct |
324
-0.98%
|
$324
$1.4 P/Share
|
|
Jun 25
2024
|
Anirvan Ghosh Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,214
-1.55%
|
$1,214
$1.4 P/Share
|
|
Jun 25
2024
|
Alexander Hieu Nguyen Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
78
-0.31%
|
$78
$1.4 P/Share
|
|
May 02
2024
|
Anirvan Ghosh Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
603
-0.77%
|
$603
$1.55 P/Share
|
|
Mar 26
2024
|
Alexander Hieu Nguyen Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+44.34%
|
-
|
|
Feb 02
2024
|
Anirvan Ghosh Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
680
-0.86%
|
$680
$1.71 P/Share
|
|
Jan 30
2024
|
Anirvan Ghosh Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,183
-1.47%
|
$1,183
$1.71 P/Share
|
|
Nov 02
2023
|
Anirvan Ghosh Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
589
-0.73%
|
$589
$1.83 P/Share
|
|
Oct 30
2023
|
Anirvan Ghosh Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,024
-1.25%
|
$1,024
$1.9 P/Share
|
|
Sep 14
2023
|
Anirvan Ghosh Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,246
-1.49%
|
$2,492
$2.47 P/Share
|
|
Aug 02
2023
|
Anirvan Ghosh Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
581
-0.69%
|
$1,162
$2.94 P/Share
|
|
Jul 31
2023
|
Anirvan Ghosh Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,020
-1.2%
|
$2,040
$2.86 P/Share
|
|
Jun 26
2023
|
Anirvan Ghosh Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,177
-1.36%
|
$3,531
$3.2 P/Share
|
|
Jun 14
2023
|
Anirvan Ghosh Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,212
-1.39%
|
$3,636
$3.39 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 20K shares |
|---|
| Open market or private sale | 5.7K shares |
|---|